Cavion is a clinical-stage pharmaceutical company with an innovative mindset and compassionate culture. Cavion closed a Series A venture capital financing in late 2016. Combining those investors’ industry capabilities with Cavion’s science and expertise has put us well on the road to developing our promising Cav3 modulators for movement disorders and rare, pediatric epilepsies. Committed to putting people in the center, Cavion’s first neurology clinical trial – the T-CALM trial of CX-8998 in essential tremor – is now recruiting subjects.
Mr. Krouse has over a decade of biotech leadership experience as founder of Tau Therapeutics LLC, Xdynia LLC and Cavion. He has been recognized for his leadership in the industry as a CIT GAP 50 Entrepreneur in the Commonwealth of Virginia and as Chairman of the Board of the Virginia Biotechnology Association. Prior to joining the pharmaceutical industry, he worked in senior university leadership including as Vice President of the University of Virginia Darden School Foundation. He also previously served as an analyst at Goldman Sachs, NYC. In addition to his roles at Cavion, he serves on the boards of the Institute for Advanced Studies in Culture and the St. Anselm Institute for Catholic Thought, organizations promoting the intellectual community at the University of Virginia. He is a frequent speaker and published author with three patents in the T-type calcium channel space. Mr. Krouse is a cum laude finance graduate of the University of Maryland Business School. He received his MALS from Georgetown University and completed The Executive Program at the Darden Graduate School of Business Administration at the University of Virginia.
Dr. Papapetropoulos is a recognized researcher, experienced biopharmaceutical executive and digital health pioneer. Prior to joining Cavion he held positions of increasing responsibility at Biogen’s Experimental Neurology Unit, Allergan’s Global Medical Affairs, Pfizer’s Neuroscience Research Unit and TEVA’s Specialty Research and Development. He has filed multiple INDs and has overseen a wide spectrum of pharmaceutical development programs leading to successful regulatory filings and new product launches. For the past 10 years he has led multiple efforts in digital health, developing standards and novel technology-based tools and solutions. Dr. Papapetropoulos is a board-certified Neurologist and holds appointments as Consultant with Massachusetts General Hospital and Voluntary Professor of Neurology with the University of Miami, Miller School of Medicine. He has authored more than 160 peer-reviewed publications and several book chapters. Dr. Papapetropoulos is a member of various government and non-profit committees on healthcare and biomedical research innovation.
Prior to joining Cavion, Ms. Heldreth had legal, research and administrative experience both as an attorney and volunteer. She was an Associate practicing in the areas of securities and mergers & acquisitions at Cleary, Gottlieb, Steen & Hamilton (NYC) and Law Clerk to the Honorable Richard J. Cardamone of the US Court of Appeals for the Second Circuit. She received her JD from The Cornell Law School and BA from St. John’s College (Annapolis).
Dr. Lee has nearly two decades of industry experience driving the discovery and development of novel drug candidates in multiple therapeutic areas and is a recognized leader in T-type calcium channel biology. Prior to joining Cavion, she was VP of Research and Translational Development at Karyopharm, where she led development of non-clinical and clinical stage pipeline candidates in oncology, infectious, autoimmune and neurodegenerative diseases. Prior to Karyopharm, she was VP of Research and Translational Medicine at Zalicus Inc. (formerly CombinatoRx), where she led the discovery and development of single agent and combination drug candidates including development of a novel T-type calcium channel modulator. Dr. Lee received her B.S. in Biology from Southampton College of Long Island University, her Ph.D. from Tufts University Sackler School and conducted her postdoctoral research at Dana-Farber Cancer Institute/Harvard Medical School. She is an author on over 30 peer reviewed publications and book chapters and an inventor on multiple patent applications and issued patents.
Dr. Boyer has over a decade of executive experience in large biotechnology and pharma companies. Dr. Boyer joined Cavion from Takeda Pharmaceuticals, Inc. where she served as a Director of Global Program Management, responsible for internal and venture development projects from discovery to market in the CNS Therapeutic Area Unit. Prior to Takeda, Dr. Boyer was a Clinical Operations Development Asset Team Lead at Biogen, Inc. in the Neurology Rare Disease Innovation Hub; and led research and development programs as a Global Clinical Operations Lead and Clinical Scientist at Pfizer, Inc. in the Neuroscience Research Unit. Dr. Boyer received her M.A. in molecular biology from Brown University and a Ph.D. in epidemiology from Walden University. In addition to holding Clinical Research Professional and National Institutes of Health Protecting Human Research Participants certifications, Dr. Boyer has contributed to the CNS field via numerous peer-reviewed publications and book chapters.
Dr. Sartori has over thirty years executive experience in big pharma and start-up companies. Dr. Sartori joined Cavion from Parexel International where he held the position of Vice President of Human Resources. He previously served as Corporate Vice President of Public Affairs and Human Resources at Bausch & Lomb, Senior Vice President of Organizational Development and Human Resources for BioTrove, Inc. (acquired by Life Technologies), Global Vice President of Human Resources at CIBA-Corning Diagnostics, Senior Vice President of HR and Communications at CIBA-Geigy, and Executive Vice-President, External Affairs and Human Resources at Novartis. Dr. Sartori received both his PhD and MBA from the University of Virginia.
Mr. Woerpel joined Cavion in 2010 as its Chief Financial Officer. He has extensive business experience serving both start-up and established companies as CFO including twenty-three years at Carden Jennings Publishing, ten years at ScholarOne (sold to Thomson Reuters) and five years at Potomac Supply Corporation. He gained public accounting experience with two years at Coopers & Lybrand in Boston and one year at Deloitte & Touche in Richmond. He has been a licensed CPA in Virginia since 1992 and received both his MS in Accounting and BS in Commerce from the University of Virginia’s McIntire School of Commerce.
Mr. Gibson served as a US Navy Supply Corps officer in Vietnam and Washington, DC before embarking on a career in international banking. He is a former Executive Vice President of Citicorp/Citibank where his positions included Group Executive of Citibank’s Global Private Bank and later Head of Global Emerging Markets, comprising Citibank’s corporate and investment banking businesses in 75 countries.
He is a member of the boards of Assyst LLC and of several boards of proprietary mutual funds distributed by the Citigroup Private Bank. He is a founding member and an emeritus Trustee of the University of Virginia’s College Foundation, an emeritus Trustee of the Darden School Foundation, the Miller Center Foundation, and James Madison’s ancestral home’s Montpelier Foundation. He remains a member of the Montpelier Steeplechase Foundation.
Mr. Gibson received his undergraduate and law degrees from the University of Virginia.
Dr. Steve Hall is a General Partner at Lilly Ventures. Dr. Hall brings more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations to Lilly Ventures. Prior to joining Lilly Ventures, Dr. Hall was Senior Vice President, Research and Development, at Serenex, Inc. (acquired by Pfizer) where he was also a co-founder. Prior to joining Serenex, Dr. Hall was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research, and information technology. He started his career as a medicinal chemist with the Squibb Institute for Medical Research and held positions of increasing responsibility for multiple projects in cardiovascular disease.
Dr. Hall is the author of more than 40 papers and 60 patents. He received his BS in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology.
Dr. Hall currently sits on the boards of Cavion, Esanex, FORMA Therapeutics, Hydra Biosciences, Lysosomal Therapeutics, Numerate and Nimbus Discovery. Steve also serves as the CEO for Esanex.
Mr. Krouse founded Cavion in 2005 and has been recognized for his leadership in the industry as a CIT GAP 50 Entrepreneur in the Commonwealth of Virginia and as Vice President of the Virginia Biotechnology Association. He has three patents in the T-type calcium channel space. Prior to founding Cavion, he worked for sixteen years in senior university leadership including as Vice President of the University of Virginia Darden School Foundation. He also previously served as an analyst at Goldman Sachs, NYC.
Mr. Krouse is a cum laude finance graduate of the University of Maryland Business School. He received his MALS from Georgetown University and completed The Executive Program at the Darden Graduate School of Business Administration at the University of Virginia.
Dr. Petukhov is a Partner at Enso Ventures where he focuses on advances in biology as well as novel therapeutics. Prior to Enso Sergei worked as a Managing Director at CLS Capital and at RUSNANO investment fund. Prior to RUSNANO, he was a strategic advisor at Kaye Scholer LLP for a number of US pharmaceutical companies.
Dr. Petukhov worked and studied at The Rockefeller University, The University of Edinburgh, The University of Cambridge, First Moscow State Medical University and Moscow State Academy of Veterinary Medicine and Biotechnology.
Mr. Weinstein is a Managing Director in Novartis Venture Fund’s Cambridge, MA office. He joined the Fund in 2006 and has been investing in venture capital since 1999.
He focuses on both medical device and biotech investments for the fund. He brings significant operating and venture capital experience to Novartis' investing efforts. He has served on many boards including Ablation Frontiers (acquired by Medtronic), Autonomic Technologies Inc., Innocrin Pharmaceuticals, Rox Medical, Sonitus Medical, Viamet Pharmaceuticals., and Visiogen (acquired by Abbott).
Prior to Novartis, Mr. Weinstein was at Prism Venture Partners, where he focused on medical devices and served on the board of Sensitech (acquired by Carrier/UTX). Prior to Prism, he was a Kauffman Fellow with Mid-Atlantic Venture Funds, where he focused on software startups. He started his career as an entrepreneur and CEO, raising angel funds to buy the assets of a defunct industrial distribution business out of bankruptcy. He then successfully restarted and built the business over the next five years.
Mr. Weinstein holds an M.B.A. with distinction from the University of Michigan Business School and a B.S. in mechanical engineering from Columbia University's School of Engineering and Applied Science. He serves on the Innovation Advisory Board of Partners Healthcare, is a member of the Virginia GAP BioLife Fund Investment Committee, and is on the advisory board of the Wolverine Venture Fund (affiliated with the University of Michigan).
Dr. D’Cruz completed undergraduate medical training at St John’s Medical College, Bangalore, India, pediatric and neurology residencies at Rush University and Medical College of Wisconsin, respectively, and obtained an MBA at the Kenan-Flagler Business School, UNC-Chapel Hill. Dr. D’Cruz is board certified in neurology/child neurology, neurophysiology, and sleep medicine, and Fellow of the American Academies of Neurology and Sleep Medicine. He has authored numerous publications.
Dr. D’Cruz was previously Professor of Neurology and Pediatrics at University of North Carolina-Chapel Hill, USA. His previous industry appointments include Medical Director, Neurology at UCB Pharma and Chief Medical Officer, Cyberonics. He currently serves on the Board of Directors of ASENT (American Society of Experimental Neuro-Therapeutics) and is the industry representative on the Pediatric Epilepsy Academic Consortium for Extrapolation (PEACE), a public-private partnership between academia, industry and patient advocacy organizations that helped develop globally harmonized regulatory pathways based on extrapolation of anti-epileptic drug efficacy data from adults to children.
In addition to industry experience in clinical development and safety monitoring, business development, regulatory interactions and public-private partnerships, Dr. D’Cruz has worked in the field of neurology for over twenty-five years, as a board-certified neurologist and epileptologist, clinical investigator, invited speaker at scientific and industry conferences, health policy and patient advocate and consultant to leading pharmaceutical companies. He maintains a clinical practice in neurology targeted towards underserved regions and population segments.
Dr. Gray is a former Associate Professor of Pathology and Director of Clinical Immunology at the University of Virginia Medical Center. Dr. Gray is a leading researcher on the role of T-type calcium channel blockers for the treatment of cancer. He is the original patent holder for the treatment of cancer via the T-type calcium channel. Dr. Gray has published over 35 peer reviewed articles and has nine patents. Dr. Gray received his medical degree from the University of Connecticut and was a Research Fellow at the University of California, San Diego, Sloan Kettering and Washington University Cancer Centers.
Dr. Macdonald is Past Chairman and Professor of Chemistry and Pharmacology at the University of Virginia. Dr. Macdonald is an expert and early pioneer in the creation of T-type calcium channel blockers for use in cancer. He has over 250 publications and 45 pending and issued patents. He is the founder of four pharmaceutical companies including Adenosine Therapeutics LLC, which sold to Clinical Data in 2008. Dr. Macdonald has shepherded four of his own compounds from the bench to the clinic and helped to oversee the development of another dozen drugs as a consultant to the pharmaceutical industry. He was a senior scientific advisor to Allergan Inc. and has served on several scientific advisory boards, including for Serenex Inc. Dr. Macdonald has been awarded numerous honors, including being twice recognized as the “Inventor of the Year” by the University of Virginia. He received his PhD from Columbia University and was a NIH Fellow at Stanford University.
600 East Water Street, Suite E
Charlottesville, VA 22902
(Please contact the Charlottesville Office for all accounting related communications)
1 Broadway, 14 FL
Cambridge, MA 02142